Navigation Links
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Date:10/13/2007

ORLANDO, Fla., Oct. 13 /PRNewswire/ -- Acutely ill, hospitalized patients with schizophrenia showed significant improvement in symptoms after taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared to SEROQUEL(R)(a) (quetiapine) and placebo. Symptom improvement was observed with INVEGA as early as five days into therapy and continued through the end of the two-week study period, according to preliminary data presented today at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida (1).

The primary endpoint was the change in the total Positive and Negative Syndrome Scale (PANSS)(b) score over the first two weeks of the study. The results showed that INVEGA achieved a significant reduction of symptoms of acutely ill, hospitalized patients, compared to SEROQUEL and placebo after two weeks of treatment (p < less than > 0.001).

"In the treatment of patients with an acute exacerbation of schizophrenia, it is important to explore medications that have the potential to achieve effective, acute symptom control. Schizophrenia patients may take two to four weeks to respond fully to treatment, so the fact that noticeable clinical improvement was observed as early as day 5 in these acutely ill patients is very important," said Miranda Chakos, M.D. Professor of Psychiatry, State University of New York at Downstate, Brooklyn, N.Y., and one of the investigators of the trial. "INVEGA is an important treatment option for patients diagnosed with schizophrenia. This trial showed beneficial effects of INVEGA in severely ill, hospitalized patients with an acute exacerbation of schizophrenia."

In the study, 399 patients with an acute exacerbation of symptoms of schizophrenia were randomized to receive INVEGA, SEROQUEL or placebo. These patients were either hospitalized or in need of hospitalization at the start of the trial and willing to remain hospitalized for a minimum of 10 days. The study involved two phases: a two-week
'/>"/>

SOURCE Janssen, L.P. and Johnson & Johnson
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
2. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
3. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
8. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
9. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
10. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
11. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Pharmavite LLC announced that Timothy "Tim" ... effective immediately. Toll recently served as Pharmavite,s executive vice ... management, private label and sales administration in ... role, Toll will expand his responsibilities to include international ... "Toll,s appointment to chief customer officer is part of ...
(Date:7/23/2014)... , July 23, 2014 Research ... the "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation ... or destroy faulty electrical pathways from sections of ... known as cardiac arrhythmias). Cardiac arrhythmias can be ...
(Date:7/23/2014)... NEW YORK , July 23, 2014 /PRNewswire/ ... Delray Beach, Fla. , is an emerging ... molecular diagnostic systems for bio-threat detection and rapid ... system called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), ... of Homeland Security ("DHS") Science & Technology directorate, ...
Breaking Medicine Technology:Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... 31, 2011 Mevion Medical Systems announced today it ... S. Lee Kling Center for Proton Therapy at the ... University School of Medicine in St. Louis MO. This ... of the first MEVION S250 proton accelerator module and ...
... 31, 2011 Royal Philips Electronics (AEX: PHI, NYSE: ... full-field digital mammography (FFDM) solution that offers a lower ... compromising image quality. The addition of MicroDose to Philips, ... for the company,s focus on women,s health care, and ...
Cached Medicine Technology:Mevion Medical Systems Delivers the World's First Superconducting Synchrocyclotron for Proton Therapy to Barnes Jewish Hospital 2Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 2Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 3Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 4
(Date:7/23/2014)... 2014 The puffiness that can appear ... techniques, according to a new guide published at the ... in the U.S. is now available for men and ... complimentary guide that is now published is meant to ... eye puffiness. While surgical techniques are available, there are ...
(Date:7/23/2014)... or Dounreay since the 1990s are not at an ... in the British Journal of Cancer today* ... at the University of Oxford and from Newcastle University ... who were under 25 and living near Sellafield or ... incidence from 1991-2006 between those living near these nuclear ...
(Date:7/23/2014)... Home Care Assistance of Oklahoma ... for seniors, announces the next installment in its ... a wide range of health and wellness-related fields. ... worker and award-winning author Nancy Kriseman, and will ... and ways to prevent burnout by becoming more ...
(Date:7/23/2014)... Lake Worth, FL (PRWEB) July 23, 2014 ... will take place Aug. 10-16, Millennium Treatment Group is ... Substance abuse has existed in society ever since man ... make wine. Substance abuse treatment has existed since shortly ... of recognizing a problem and then developing a way ...
(Date:7/23/2014)... By Alan Mozes ... -- U.S. servicemen are more likely to have been exposed ... a large, new survey suggests. The finding seems to ... team suggested that the finding could be a cause for ... physical, mental, and/or sexual abuse among the civilian population has ...
Breaking Medicine News(10 mins):Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3
... DIEGO, Feb. 2 MedWaves, Inc. announces the ... Certification. This is in addition to having already ... Company,s patented Microwave Coagulation/Ablation System for surgical applications. ... surgeons and interventional radiologists to treat soft tissue ...
... Full Year Expectations for Revenue GrowthBRAINTREE, Mass., Feb. 2 ... reported third quarter fiscal 2009 GAAP net revenues of ... up 25%; and net earnings per share of $0.62, ... up 18%; operating income is $67 million, up 35%; ...
... study says , , MONDAY, Feb. 2 (HealthDay News) -- ... people who sleep too little or too much, according ... , Previous studies have linked both short and long ... disease, diabetes, obesity, and death. Chronic elevations in inflammation-regulating ...
... Feb. 2 A 74-year-old prostate,cancer patient has become ... a,new, faster form of radiotherapy that extends more advanced ... the faster treatment,using RapidArc radiotherapy technology from Varian Medical ... The patient, a retired military aircraft engineer from ...
... Xmark Opportunity Partners, LLC ("Xmark"), the sole member of the ... Fund, Ltd., has, in the past, sent letters to the ... ) setting forth its dissatisfaction with the company,s corporate governance, ... this opportunity to respond to the Form 8-K filed by ...
... will drive adhesion barrier market, according to Millennium ... According to Millennium Research Group,s (MRG,s) US ... Adhesion Barriers 2009 report, growing surgeon interest ... launches, will fuel revenues in the US adhesion ...
Cached Medicine News:Health News:MedWaves, Inc. Announces Receipt of MDD CE Certification and Additional U.S. FDA 510(k) Clearance to Market Its Patented Microwave Coagulation/Ablation System and Devices 2Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 2Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 3Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 4Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 5Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 6Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 7Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 8Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 9Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 10Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 11Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 12Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 13Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 14Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 15Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 16Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 17Health News:Inflammation May Play Role in Sleep Duration 2Health News:Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems 2Health News:Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems 3Health News:Adhesion Barrier Market to Skyrocket to Over $550 Million by 2013 2Health News:Adhesion Barrier Market to Skyrocket to Over $550 Million by 2013 3
... Fit™ is the innovative, new padding system ... cushions bony prominences and contours to the ... other padding around. Plus, Gel Fit's proprietary ... creating a vacuum seal when the brace ...
... Flex™ might just be the world's ... for functional support, post-op/rehab support, or both, ... Flex's new Accutrac™ ROM hinges control flexion ... provides long-term durability while being heat-moldable to ...
... state-of-the-art laser scanning technology for an anatomically-contoured, ... lean, athletic legs. Offering the same ... Flex Sport's "second skin" fit conforms to ... no other off-the-shelf knee brace., ,Indications: ...
... CartiCare enables unloading of the medial or ... with unicompartmental osteoarthritis. Plus, we equipped this ... hinge, making it further suitable for post-op ... and/or adjustable flexion/extension control. , ,Indications: ...
Medicine Products: